“2013 was a positive year for our Company, notwithstanding the lower silver price environment.” said , President and CEO.
Net loss of , or per share, in the year ended , compared to net earnings of or per share in the year ended . The lower net earnings in 2013 are principally due to pre-tax impairment charges and inventory write-downs of .
PS: And no, it’s not just SSRI. By way of just one more example (from several on offer), a few of us here in the backrooms had a jolly good guffaw and chortle over Kinross’s (KGC) (K.to) 4q13 NR a few days ago. That one included J. Paul Rollinson CEO stating…:
“Operational excellence, combined with a focus on financial discipline and a strong balance sheet, underpinned Kinross’s solid performance in 2013.
And also some numbers :
Reported net loss (3): $740.0 million, or $0.65 per share, compared with net loss of $2,984.9 million, or $2.62 per share, in Q4 2012. The Q4 reported net loss includes an after-tax non-cash impairment charge of $544.8 million, primarily comprised of property, plant and equipment at Maricunga. Full-year reported net loss was $3,012.6 million, or $2.64 per share, compared with a net loss of $2,546.2 million, or $2.24 per share for full-year 2012. Reported net loss for the full year also includes an after-tax non-cash impairment charge of $2,289.3 million, previously reported on July 31, 2013.